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Cancer is a complex collection of distinct genetic diseases united by common hallmarks. Here, 
we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis. We 
describe a conceptual framework of how oncogene and non-oncogene addictions contribute to 
these hallmarks and how they can be exploited through stress sensitization and stress overload to 
selectively kill cancer cells. In particular, we present evidence for a large class of non-oncogenes 
that are essential for cancer cell survival and present attractive drug targets. Finally, we discuss 
the path ahead to therapeutic discovery and provide theoretical considerations for combining 
orthogonal cancer therapies.The Current State of Cancer Research
The past two decades have witnessed tremendous advances 
in our understanding of the pathogenesis of cancer. It is now 
clear that cancer arises through a multistep, mutagenic pro-
cess whereby cancer cells acquire a common set of properties 
including unlimited proliferation potential, self-sufficiency in 
growth signals, and resistance to antiproliferative and apop-
totic cues. Furthermore, tumors evolve to garner support 
from surrounding stromal cells, attract new blood vessels to 
bring nutrients and oxygen, evade immune detection, and ulti-
mately metastasize to distal organs (Hanahan and Weinberg, 
2000). Many of these phenotypic traits can be brought about 
by genetic alterations that involve the gain-of-function muta-
tion, amplification, and/or overexpression of key oncogenes 
together with the loss-of-function mutation, deletion, and/
or epigenetic silencing of key tumor suppressors (Hahn and 
Weinberg, 2002).
Cancer cells achieve these phenotypes in large part by reac-
tivating and modifying many existing cellular programs nor-
mally used during development. These programs control coor-
dinated processes such as cell proliferation, migration, polarity, 
apoptosis, and differentiation during embryogenesis and tis-
sue homeostasis. Consistent with Darwinian principles, cancer 
evolves through random mutations and epigenetic changes 
that alter these pathways followed by the clonal selection of 
cells that can survive and proliferate under circumstances that 
would normally be deleterious.
Although a number of oncogenes and tumor suppressors, 
such as PI3K, Ras, p53, PTEN, Rb, and p16INK4a, are frequently 
mutated in cancer cells, there also appears to be a large num-
ber of low-frequency changes that can contribute to onco-
genesis. Indeed, data from tumor sequencing projects reveal 
an astounding diversity of mutations in tumors. In one study, 
Stratton and colleagues estimate that individual mutations in 
as many as 20% of all kinases can play an active role in tumori-
genesis (Greenman et al., 2007), although it remains to be seen whether mutations in 20% of other gene classes will also drive 
tumorigenesis. Large-scale sequencing of multiple cancers 
has so far failed to identify new, high-frequency mutation tar-
gets in addition to those previously identified (Cancer Genome 
Atlas Research Network, 2008; Ding et al., 2008; Jones et al., 
2008; Parsons et al., 2008; Sjoblom et al., 2006; Wood et al., 
2007). Rather, these studies found that every tumor harbors a 
complex combination of low-frequency mutations thought to 
drive the cancer phenotype. Furthermore, the repertoires of 
somatic mutations in different cancer types such as breast and 
colon cancers appear to be different. Although there is much 
debate with regard to the statistical requirements needed to 
distinguish likely driver from noncontributing passenger muta-
tions among the large collection of mutations in tumors, it is 
clear that there is tremendous complexity and heterogeneity in 
the patterns of mutations in tumors of different origins.
The complexity of alterations in cancer presents a daunting 
problem with respect to treatment: how can we effectively treat 
cancers arising from such varied perturbations? Cancer cells 
have extensively rewired pathways for growth and survival that 
underlie the malignant phenotype. Thus, a key to successful 
therapy is the identification of critical, functional nodes in the 
oncogenic network whose inhibition will result in system fail-
ure, that is, the cessation of the tumorigenic state by apop-
tosis, necrosis, senescence, or differentiation. Furthermore, 
therapeutic agents attacking these nodes must display a suf-
ficiently large therapeutic window with which to kill tumor cells 
while sparing normal cells. To borrow a term from yeast and 
fly genetic analyses, the therapeutic agents must constitute 
“synthetic lethality” with the cancer genotype/phenotype (Kae-
lin, 2005). In some cases, particular agents can display geno-
type-dependent lethality similar to synthetic lethality without 
directly inhibiting a particular protein. The two mainstay treat-
ment options for cancer today—chemotherapy and radiation—
are examples of agents that exploit the enhanced sensitivity 
of cancer cells to DNA damage. Despite all of our knowledge, Cell 136, March 6, 2009 ©2009 Elsevier Inc. 823
however, we still do not have a clear molecular understanding 
of why these agents work to selectively kill tumor cells and, 
conversely, why they eventually fail. The advent of “targeted” 
therapies, which aim to attack the underlying oncogenic con-
text of tumors, provides more sophisticated examples of syn-
thetic lethality. When properly deployed, these therapies tend 
to be more effective relative to chemotherapy and radiation.
Additional Hallmarks: The Stress Phenotypes of Cancer
Although there is no simple way to predict a priori which pro-
teins will act as nodal points to generate cancer drug targets, 
solutions are likely to emerge from multiple sources, includ-
ing recent initiatives to understand cancer at the systems level. 
From a genetic point of view, it is important to appreciate that 
the plethora of mutations observed in the cancer genome must 
ultimately result in a common set of hallmarks in order to bring 
about the malignant phenotype. The goal of cancer therapy is, 
therefore, to either reverse these properties or target them as 
tumor-specific liabilities, preferably through the combinatorial 
application of a relatively small number of drugs. Thus we need 
a thorough understanding of the nature of these hallmarks.
In addition to the six hallmarks outlined in the seminal review 
by Hanahan and Weinberg (Hanahan and Weinberg, 2000) that 
collectively promote survival and proliferation in foreign envi-
ronments (Figure 1, top), as well as the hallmark of “evading 
immune surveillance” proposed by Kroemer and colleagues 
(Kroemer and Pouyssegur, 2008) (Figure 1, left), we propose 
a number of additional, equally prevalent hallmarks of can-
cer cells based on recent analyses of cellular phenotypes. 
Although these cancer phenotypes are not responsible for 
initiating tumorigenesis, they are common characteristics of 
many tumor types (Figure 1, bottom). Among these additional 
hallmarks are DNA damage/replication stress, proteotoxic 
stress, mitotic stress, metabolic stress, and oxidative stress. 
We collectively refer to this subset as 
the stress phenotypes of cancers. There 
are often intricate functional interplays 
among these shared hallmarks of tumor 
cells, which are illustrated in Figure 1 and 
discussed below. Although some of these stress phenotypes 
are not unique to cancer cells and can be observed in other 
conditions such as chronic inflammation, we propose that they 
represent a common set of oncogenesis-associated cellular 
stresses that cancer cells must tolerate through stress support 
pathways. How these phenotypes arise is not well understood, 
but targeting these hallmarks and their associated vulnerabili-
ties in a wide variety of cancers has shown promise for thera-
peutic intervention.
DNA Damage and DNA Replication Stress
Based on karyotypic and mutational analyses, it is clear 
that tumors, especially solid tumors, pass through stages of 
extreme genomic instability that result in the accumulation of 
point mutations, deletions, complex chromosomal rearrange-
ments, and extensive aneuploidy (Hartwell and Kastan, 1994). 
This level of instability is due in part to a constitutive level of 
endogenous DNA damage, which results in activation of the 
DNA damage stress response (DDR) pathway (Bartkova et al., 
2005; Gorgoulis et al., 2005). Elevated levels of DNA damage 
observed in early stage tumors are thought to be due to sev-
eral factors. First, the shortening of telomeres due to replica-
tion in the absence of sufficient telomerase activity leads to 
the appearance of double-strand breaks (DSBs) at telomeric 
ends. The subsequent fusions of these deprotected ends initi-
ate breakage-fusion-bridge cycles that result in translocations 
and gene amplification events (Maser and DePinho, 2002). 
DSBs resulting from replication stress can also lead to break-
age-fusion-bridge cycles (Windle et al., 1991). Additionally, 
oncogene activation in precancerous lesions has been shown 
to increase DSBs and genomic instability (Halazonetis et al., 
2008), possibly through DNA hyper-replication (Bartkova et al., 
2006; Di Micco et al., 2006). Finally, mutation of genes involved 
in either DNA repair programs (such as excision, crosslink, or 
mismatch repair) or the DDR pathways (such as ATM and p53 
Figure 1. The Hallmarks of Cancer
In addition to the six hallmarks originally proposed 
by Hanahan and Weinberg (top half, white sym-
bols) and evasion of immune surveillance pro-
posed by Kroemer and Pouyssegur, we propose 
a set of additional hallmarks that depict the stress 
phenotypes of cancer cells (lower half, colored 
symbols). These include metabolic stress, proteo-
toxic stress, mitotic stress, oxidative stress, and 
DNA damage stress. Functional interplays among 
these hallmarks promote the tumorigenic state and 
suppress oncogenic stress. For example, the utili-
zation of glycolysis allows tumor cells to adapt to 
hypoxia and acidify its microenvironment to evade 
immune surveillance. Increased mitotic stress 
promotes aneuploidy, which leads to proteotoxic 
stress that requires compensation from the heat 
shock response pathway. Elevated levels of reac-
tive oxygen species result in increased levels of 
DNA damage that normally elicits senescence or 
apoptosis but is overcome by tumor cells.824 Cell 136, March 6, 2009 ©2009 Elsevier Inc.
signaling) can lead to increased DNA damage, inappropriate 
cell-cycle progression, and genomic instability (Harper and 
Elledge, 2007). In normal cells, DNA damage signals to halt 
proliferation, induce cellular senescence, or elicit apoptosis. 
Cancer cells have evolved to overcome the antiproliferative 
effects of DNA damage, continuing to replicate in the presence 
of damage (Figure 1).
Proteotoxic Stress
Tumors exhibit proteotoxic stress evidenced by their frequent 
constitutive activation of the heat shock response. We think 
this is due, in part, to the striking degree of aneuploidy (altered 
chromosome number) often found in solid tumors (Figure 1) 
(Ganem et al., 2007; Torres et al., 2008; Williams et al., 2008). 
Aneuploidy and gene copy-number changes can alter the rela-
tive balance of growth and survival signals, thereby promot-
ing tumorigenesis. However, they also result in correspond-
ing increases and decreases in transcript levels (Pollack et 
al., 2002; Torres et al., 2007; Tsafrir et al., 2006) that produce 
imbalances in the stoichiometry of protein complex subunits 
(Papp et al., 2003). These imbalances increase the amount of 
toxic, unfolded protein aggregates in the cell and place addi-
tional burdens on the protein folding and degradation machin-
eries (Denoyelle et al., 2006). This proteotoxic stress is coun-
teracted, in part, by the heat shock response pathway, which 
promotes the proper folding and/or proteolytic degradation of 
proteins (Whitesell and Lindquist, 2005).
Mitotic Stress
A subset of tumors display increased rates of chromosome 
mis-segregation, which is referred to as the CIN (chromosome 
instability) phenotype (Komarova et al., 2002). This instability 
results in a shifting chromosome distribution, thus allowing 
tumor cells to rapidly evolve. In principle, CIN phenotypes can 
result from defects in a variety of pathways involved in mitosis, 
including defects in mitotic proteins that execute chromosome 
segregation and defects in the spindle assembly checkpoint, 
which coordinates anaphase entry with proper alignment of 
chromosomes on the mitotic spindle (Cahill et al., 1998). In 
addition, the CIN phenotype could result from the presence of 
extra centrosomes in tumor cells or from stresses placed on 
the mitotic apparatus due to the need to segregate supernu-
merary chromosomes (Ganem et al., 2007). Furthermore, CIN 
and mitotic stress might arise indirectly as a result of DSBs 
and genomic instability following oncogene activation, even in 
lesions where the mitotic machinery is intact (Halazonetis et 
al., 2008). Mutations in certain oncogenes, such as Ras, and 
tumor suppressors, such as p53, have been suggested to con-
tribute to the CIN phenotype (Denko et al., 1994). However, the 
precise cause of mitotic stress is not known for the vast major-
ity of tumors.
Metabolic Stress
Normal cells derive the bulk of their ATP through mitochondrial 
oxidative phosphorylation. In what has been referred to as the 
Warburg effect, most cancer cells are found to predominantly 
produce energy by the less efficient method of glycolysis and 
secrete a large amount of lactic acid, even under high oxygen 
conditions (Warburg, 1956). Tumor cells exhibit dramatically 
increased glucose uptake and highly elevated rates of glycoly-
sis (DeBerardinis et al., 2007). This provides the basis for tumor imaging by positron emission tomography (PET) using the glu-
cose analog 18F-2-deoxyglucose. This transition to glycoly-
sis for energy production provides several advantages to the 
tumor including adaptation to a low oxygen environment and 
the acidification of the surrounding microenvironment, which 
promotes tumor invasion and suppresses immune surveillance 
(Figure 1).
Oxidative Stress
The defining characteristic of oxidative stress is the presence 
of reactive oxygen species (ROS), and cancer cells typically 
generate more ROS than normal cells (Szatrowski and Nathan, 
1991). Both oncogenic signaling (Lee et al., 1999) and the 
downregulation of mitochondrial function (Gogvadze et al., 
2008) in tumors can contribute to ROS generation. ROS are 
highly reactive and likely to contribute to the increased levels 
of endogenous DNA damage observed in cancer cells (Figure 
1). In addition, ROS are important signaling mediators, and 
their presence may contribute to transformation. For example, 
ROS promote the activation of the transcription factor HIF-1 
by hypoxia (Dewhirst et al., 2008), and HIF-1 can promote the 
glycolytic switch and angiogenesis observed in tumors.
Attacking the Hallmarks of Cancer
Any therapy with the stated goal to treat and possibly cure can-
cer must show differential toxicity toward tumor cells relative 
to normal cells. Implicit in this statement is that some unique 
properties of cancer cells not shared by normal cells, such as 
those depicted in Figure 1, must be exploited to the specific 
detriment of cancer cells, i.e., the concept of synthetic lethal-
ity. In principle, cancer can be treated by inducing cancer cells 
to undergo apoptosis, necrosis, senescence, or differentia-
tion. These changes can be brought about by disrupting can-
cer cell-autonomous processes, by interfering with autocrine/
paracrine signaling within tumors, or by blocking heterotypic 
signaling between tumor cells and the surrounding stromal tis-
sue or blood vessels. Enhancing immune surveillance against 
cancer cells expressing novel antigens is also an attractive 
approach that has shown efficacy in specifically killing cancer 
cells (Muller and Scherle, 2006).
Experiments aimed at either suppressing oncogene activ-
ity or restoring tumor suppressor function have revealed that 
such intervention is highly deleterious to the cancer cell. The 
heightened state of dependency of cancer cells on oncogenes 
and the loss of tumor suppressors led to the terms “oncogene 
addiction” (OA) and “tumor suppressor gene hypersensitivity” 
(Weinstein, 2002; Weinstein and Joe, 2008). These alterations 
are necessary for both the establishment and maintenance 
of the oncogenic state and therefore are logical drug targets. 
Indeed, much effort has been extended to pharmacologically 
inhibit oncoproteins. What is thought to underlie the phenom-
enon of oncogene addiction is the observation that oncogenes 
elicit strong, opposing prosurvival and proapoptotic signals in 
cancer cells that favor growth and survival, and the acute inhi-
bition of oncogene function tilts this balance toward cell death 
(Downward, 2003; Sharma and Settleman, 2007).
To bring about their phenotypic manifestations, oncogenes 
rely on extensive adaptations in cellular processes that are 
themselves not oncogenic. In addition, cancer cells may also Cell 136, March 6, 2009 ©2009 Elsevier Inc. 825
Table 1. Cancer Therapies Targeting Various Hallmarks of Cancer
Agent Target Addiction Hallmarks Potential mechanisms References
17AAG  
(small molecule)
HSP90 NOA A geldanamycin analog that binds to the 
ATP-binding pocket of HSP90 and inhibits its 
catalytic activity
Whitesell and 
Lindquist, 2005
1MT, MTH-Trp  
(small molecule)
IDO NOA Inhibits tryptophan catabolism in tumor mi-
croenvironment to allow T cell proliferation
Muller and Scherle, 
2006
5-fluorouracil  
(small molecule)
DNA NOA Inhibits pyrimidine metabolism, incorporation in 
to DNA and RNA causes cell-cycle arrest
Longley et al., 2003
ABT-737, ABT-263 
(small molecule)
BCL-XL, BCL-2 OA Bind to the BH3 pocket of Bcl-XL and inhibit its 
antiapoptotic function
Stauffer, 2007
Alvocidib, PD 0332991 
(small molecule)
CDKs OA Inhibit CDKs and induce cell-cycle arrest Lee and Sicinski, 
2006
AP 12009  
(antisense oligo)
TGFβ 2 NOA
   
Inhibits tumor autocrine and paracrine signal-
ing, reverses immune suppression in the tumor 
microenvironment
Muller and Scherle, 
2006
AZD2281, AG014699 
(small molecule)
PARP1 NOA Inhibit base excision repair in homologous 
recombination repair-deficient cancer cells
Bryant et al., 2005; 
Farmer et al., 2005
Bevacizumab  
(antibody)
VEGF NOA Inhibits endothelial cell recruitment and tumor 
vasculature
Folkman, 2007
BEZ235  
(small molecule)
PI3K OA
 
Causes cell-cycle arrest in tumor cells and 
inhibits tumor angiogenesis
Maira et al., 2008
Bortezomib  
(small molecule)
Proteasome NOA Inhibits the catalytic activity of 26S proteasome 
and induces apoptosis
Roccaro et al., 
2006
Celecoxib  
(small molecule)
COX2 NOA
   
Reverses immune suppression in the tumor 
microenvironment, inhibits tumor autocrine and 
paracrine signaling
Muller and Scherle, 
2006
Cisplatin and analogs 
(small molecule)
DNA NOA Induces DNA crosslinks Siddik, 2003
Erlotinib, Gefitinib 
(small molecule)
EGFR OA
 
Inhibit EGFR tyrosine kinase by competing with 
ATP binding
Sharma et al., 2007
GRN163L  
(modified oligo)
hTERT OA Mimics telomere sequence and inhibits the 
hTERT active site
Dikmen et al., 
2005; Harley, 2008
GRNVAC1  
(cell therapy)
hTERT OA
 
Autologous dendritic cells transduced to ex-
press an hTERT-LAMP fusion protein to elicit T 
cell response to hTERT + tumor cells
Harley, 2008; Su et 
al., 2005
GV1001  
(peptide)
hTERT OA
 
A short immunogenic peptide from hTERT 
designed to elicit T cell response against hTERT 
+ tumor cells
Harley, 2008; 
Nava-Parada and 
Emens, 2007
Imatinib, Dasatinib 
(small molecule)
BCR-ABL, c-Kit, 
Src, PDGFR, 
other TKs
OA
 
Tyrosine kinase inhibitor with multiple targets Quintas-Cardama 
et al., 2007
Mapatumumab, Lexa-
tumumab (antibody)
TRAIL receptor NOA Bind and activate TRAIL receptors to induce 
apoptosis
Carlo-Stella et al., 
2007
Methotrexate  
(small molecule)
DHFR NOA Inhibits thymidine biosynthesis and induces 
replicative stress
McGuire, 2003
Nutlin-3  
(small molecule)
HDM2 OA
 
Binds to HDM2 and inhibits the binding and 
ubiquitination of p53
Vassilev, 2007
Oblimersen  
(antisense oligo)
BCL-2 OA Inhibits the expression of BCL-2 by blocking 
translation of its mRNA
Moreira et al., 2006
Paclitaxel, Vinblastine 
(small molecule)
Mitotic spindle NOA Interfere with dynamics and stability of mitotic 
spindles, activate mitotic checkpoints, and 
induce chromosome mis-segregation
Weaver and Cleve-
land, 2005
PF-00477736  
(small molecule)
Chk1 NOA Prevents activation of the DNA damage re-
sponse, leading to persistent DNA damage and 
replication stress
Ashwell and Zablu-
doff, 2008
PRIMA-1, MIRA-1 
(small molecule)
Mutant p53 TSGH
 
Reactivate the function of mutant p53 Selivanova and 
Wiman, 2007
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Rapamycin, RAD001, 
Temsirolimus  
(small molecule)
mTOR NOA
 
Inhibit protein synthesis Guertin and Saba-
tini, 2007
Retinoic acid  
(small molecule)
RAR, RXR OA Induces cellular differentiation Spira and Car-
ducci, 2003
SAHBs  
(stapled peptide)
BCL-XL, BCL-2 OA Stapled BH3 domains that bind to BCL-2 family 
members and promote apoptosis
Verdine and Walen-
sky, 2007
Sorafenib, Sunitinib 
(small molecule)
Multiple kinases 
(VEGFR, RAF, 
c-Kit, PDGFR)
NOA Inhibit endothelial cell recruitment and tumor 
vasculature
Folkman, 2007
Topotecan, Irinotecan 
(small molecule)
Topo-isomerase I NOA Induce DNA breaks Pommier, 2006
Trastuzumab  
(antibody)
ERBB2 OA
  
Inhibits ERBB2 activation and induces immune 
destruction of cancer cells
Hynes and Lane, 
2005
Therapeutics are selected based on the diversity of their chemical structures, the hallmarks they attack, and their cellular targets. These agents are 
either investigational drugs or approved for selective oncology indications. Abbreviations: OA, oncogene addiction; NOA, non-oncogene addiction; 
TSGH, tumor suppressor gene hypersensitivity. Symbols for each hallmark refer to those used in Figure 1.
Table 1. Continued
Agent Target Addiction Hallmarks Potential mechanisms Referencesdisplay an increased dependence on the normal cellular func-
tions of certain genes that act in oncogenic pathways but 
are not themselves classical oncogenes. For example, muta-
tions in many genes in a given oncogenic pathway are unable 
to directly promote tumor formation because, despite being 
required for their pathway, they cannot increase the over-
all activity of the pathway because they are not rate-limiting. 
However, a reduction in the activity of many such genes can 
become rate-limiting to the pathway in question, and thus, 
they represent potential drug targets. By this rationale, cancer 
cells are addicted to both oncogenes and non-oncogenes. To 
describe this addiction of cancer cells to the functions of non-
oncogenes, we have termed this phenomenon “non-oncogene 
addiction,” NOA (Solimini et al., 2007). Although NOA genes, 
like oncogenes, are required for maintenance of the tumori-
genic state, NOA genes do not undergo oncogenic mutations 
or functionally significant genomic alterations in tumors. The 
concept of non-oncogene addiction underscores the impor-
tant contribution of these supporting networks to oncogenesis 
and highlights the potential of non-oncogenes as points of 
intervention for cancer therapeutics.
Whereas some gene classes and pathways fall neatly into the 
OA or NOA designations, others are more difficult to categorize 
because they exhibit characteristics of both phenomena. For 
example, interferon regulatory factor 4 (IRF4) (Iida et al., 1997) 
is oncogenic and overexpressed due to translocations in some 
multiple myelomas. However, it is also required for the survival 
of myelomas lacking IRF4 translocations or overexpression 
(Shaffer et al., 2008). Should it be considered as an example 
of OA in the latter cases? Also, should a protein that is directly 
activated by an oncogene and required for tumorigenesis—
but is otherwise not mutated in cancer—be considered an 
example of NOA when it is so clearly linked to an oncogene? 
Both examples are clear if one adheres to a strict definition of 
NOA stating that NOA genes do not undergo oncogenic muta-
tions in tumors. However, these examples often run counter to 
our overall intuitive sense of the different categories. Regard-
less, although the OA and NOA designations are not perfect, they provide a useful intellectual framework for thinking about 
cancer cell vulnerabilities and the principles of cancer thera-
pies. Below, we will discuss examples of oncogene and non-
oncogene addiction and describe how modern tools are being 
applied to identify these classes of genes for possible thera-
peutic exploitation.
Oncogene Addiction and Tumor Suppressor Gene 
Hypersensitivity
Despite the multitude of genetic and epigenetic alterations found 
across cancers, a given tumor is likely to be driven by only a 
select few changes—those that result in the gain of an oncogene 
or the loss of a tumor suppressor. The phrase “oncogene addic-
tion” was coined to describe the observation that tumor main-
tenance often depends upon the continued activity of certain 
oncogenes (Weinstein, 2002). This phenomenon has been dem-
onstrated in vivo for several oncogenes. For example, mouse 
models using an inducible MYC oncogene have shown that MYC-
driven skin papillomas, lymphomas, and osteosarcomas can all 
be reversed upon MYC withdrawal (Felsher and Bishop, 1999; 
Jain et al., 2002; Pelengaris et al., 1999). Similarly, addictions to 
the HRAS or BCR-ABL oncogenes have been demonstrated in 
mouse models of melanoma and leukemia, respectively (Chin 
et al., 1999; Huettner et al., 2000). In human colorectal cancer 
cells bearing a KRAS mutation, somatic knockout of the KRAS 
oncogene results in reversion of the transformed phenotype and 
abrogates the ability of these cells to form tumors in nude mice 
(Shirasawa et al., 1993).
The subset of oncogenes whose inhibition can lead to tumor 
cell death, differentiation, arrest, or senescence is of great clin-
ical interest as targets for cancer therapeutics (Table 1). This 
strategy has proven successful for the protein kinase onco-
genes BCR-ABL (imatinib/Gleevec), EGFR (gefitinib/Iressa, 
erlotinib/Tarceva), and HER2 (trastuzumab/Herceptin) (Druker, 
2002; Roberts and Der, 2007; Sharma et al., 2007), and efforts 
toward inhibition of BRAF, MDM2, and the lipid kinase PI3K are 
underway. Targeting non-kinase oncogenes such as RAS and 
MYC, however, has proven more difficult.Cell 136, March 6, 2009 ©2009 Elsevier Inc. 827
In contrast to oncogenes, tumor suppressor genes act to 
provide the cellular restraints necessary to prevent aberrant 
growth and survival or genomic instability. Loss of tumor 
suppressor genes through deletion, inactivating mutation, or 
epigenetic silencing results in the removal of these restraints 
leading to tumorigenesis. Reintroduction of a tumor suppres-
sor gene into a tumor lacking that gene can result in tumor 
regression. This concept has been recently demonstrated 
by reactivation of p53 in mouse tumor models (Martins et 
al., 2006; Ventura et al., 2007; Xue et al., 2007). Pharmaco-
logical exploitation of tumor suppressor mutations, however, 
has lagged behind efforts aimed at oncogenes because it 
is often difficult to use a small molecule to either restore 
or mimic the function of a protein that is either mutated or 
absent. In cases where a tumor suppressor negatively regu-
lates the activity of a proto-oncogene, drugs targeting the 
corresponding proto-oncogene should prove efficacious in 
treating tumors lacking that tumor suppressor. For exam-
ple, tumors that have lost the tumor suppressor and lipid 
phosphatase PTEN, which normally acts to constrain PI3K 
signaling, are likely to be sensitive to PI3K inhibitors. Simi-
larly, loss of Rb, p16, p21, or p27 all result in upregulation of 
cyclin-dependent kinase (CDK) activity, which drives cell-
cycle entry. In principle, tumors resulting from these lesions 
might be more sensitive to CDK inhibitors. Whether such 
predictions prove true will only become apparent from clini-
cal trials employing PI3K and CDK inhibitors. In many other 
cases, however, such as those involving loss of the tumor 
suppressors p53 or ARF, there is no obvious positive signal-
ing pathway to target, and alternative therapeutic strategies 
must therefore be considered.
Targeting Non-oncogene Addiction for Cancer Therapy
We proposed the concept of non-oncogene addiction (NOA) 
based on the understanding that the tumorigenic state depends 
on the activities of a wide variety of genes and pathways, many 
of which are not inherently oncogenic themselves (Solimini et 
al., 2007). Importantly, these genes and pathways are essen-
tial to support the oncogenic phenotype of cancer cells but are 
not required to the same degree for the viability of normal cells. 
From a purely genetic point of view, these dependencies should 
provide an ample number of drug targets that when inhibited will 
constitute synthetic lethality with the underlying tumor genotype. 
Gene interaction studies in yeast have provided precedence 
for this notion. For example, most mutations exhibit enhanced 
growth defects when paired with certain other mutations, and 
one study in yeast identified an average of six genetic interac-
tions per gene (Collins et al., 2007). As a tumor contains many 
genetic alterations, each of these changes provides an opportu-
nity to pair with the loss of function of a second gene to result in 
a severe and possibly lethal growth and survival phenotype. Fur-
thermore, if this second gene is targeted with a drug that inhibits 
its protein, then a potential cancer therapy can result.
NOA genes and pathways provide important targets for anti-
tumor therapies. In the sections below, we will discuss general 
classes of NOA genes with specific examples when available. 
NOA genes fall into two general categories, tumor intrinsic and 
tumor extrinsic. Whereas tumor-intrinsic NOA genes support 828 Cell 136, March 6, 2009 ©2009 Elsevier Inc.the oncogenic state of the tumor cell in a cell-autonomous 
manner, tumor-extrinsic NOA genes function in stromal and 
vascular cells that provide heterotypic support for the tumor. 
An advantage of targeting these accessory cells is that, unlike 
tumor cells, they tend to be genetically more stable and there-
fore are less likely to evolve drug resistance. However, in cer-
tain circumstances tumors may be able to evolve reduced 
dependency on these accessory cells.
The trade-off for the tumorigenic state is that tumor cells 
experience numerous cellular stresses not experienced by 
normal cells and therefore tumor cells are more dependent on 
stress support pathways for their survival. In principle, there 
are two approaches to exploit this dependency to selectively 
kill tumor cells. The first approach, stress sensitization, aims 
to diminish the activity of the stress support pathways such 
that the tumor cell can no longer cope with the stress of its 
oncogenic state and either ceases to proliferate or initiates 
apoptosis or necrosis. The second approach, stress overload, 
aims to exacerbate existing oncogenic stress in order to over-
whelm the stress support pathways in the tumor cell, leading 
to growth arrest or cell death. Both approaches, therefore, dis-
rupt the balance of pro- and antisurvival signaling to the detri-
ment of tumor cells. Examples of specific types of NOA are 
illustrated in Figure 2 and discussed below.
Intrinsic Non-oncogene Addiction
DNA Damage and Replication Stress
In nearly all tumor cell types, the rate of spontaneous DNA 
damage and the degree of replication stress are enhanced. 
The presence of oncogenes can also elicit substantial DNA 
damage (Halazonetis et al., 2008). DNA damage stress can be 
exploited therapeutically through both stress sensitization and 
stress overload. An elaborate DNA damage response (DDR) 
pathway exists in the cell to ameliorate the effects of DNA dam-
age by promoting DNA repair. Mutations in genes of this path-
way result in increased sensitivity to DNA damage (Harper and 
Elledge, 2007). In principle, cells experiencing spontaneous 
DNA damage should show enhanced sensitivity to agents that 
interfere with this stress response pathway (Figure 2). In sup-
port of this notion, recent studies have shown that inhibitors 
of the DDR kinases ATM and Chk1 exhibit selective toxicity 
toward cancer cells (Chen et al., 2006; Kennedy et al., 2007). 
Although it seems counterintuitive that a pathway that normally 
serves to restrain proliferation and promote apoptosis would 
protect a cancer cell, the DNA repair and genomic stability 
afforded by this pathway could save a cancer cell from death 
caused by persistent DNA damage and replication stress.
Stress overload of the DDR pathway should also show effi-
cacy in cancer treatment. Although it is not clear why DNA-
damaging agents, such as IR and chemotherapy, are effective 
cancer therapies, it is possible that these are examples of stress 
overload, where cancer cells with already elevated levels of DNA 
damage and replication stress cannot repair the additional dam-
age inflicted by these agents. An alternative explanation is that 
during tumorigenesis, the persistence of DNA damage selects 
for cells with mutations that abrogate part of the DDR pathway 
and therefore cannot properly sense and respond to DNA dam-
age. These cells with a partially defective DDR might therefore 
Figure 2. Examples of Non-oncogene Addictions in Cancer Cells
The tumorigenic state results in a variety of alterations (shown on top), which are related to the hallmarks described in Figure 1. These alterations give rise to 
a number of potentially deleterious circumstances or vulnerabilities (detailed in the bottom half) that could be lethal to the tumor cells if left unchecked. The 
existence of stress support pathways (shown in red) help suppress this lethality. Many of these pathways are examples of non-oncogene addiction (NOA), and 
therapeutics that interfere with their functions could display synthetic lethality with the tumor genotype/phenotype.be more vulnerable to the extensive DNA damage resulting from 
radiation or chemotherapy that is lethal without a normal DDR 
pathway. In this context, DNA damage exploits a stress pheno-
type of tumors that is analogous to non-oncogene addition.
Given the sensitivity of many cancers to DNA-damaging 
agents, there should exist genes whose inhibition will generate 
endogenous DNA damage to exacerbate this sensitivity. Exem-
plifying this phenomenon are cancers bearing BRCA2 mutations. 
These tumors are defective in homologous recombination-medi-
ated DNA repair and are particularly sensitive to DNA crosslinkers 
such as cisplatin (Sakai et al., 2008). Furthermore, these tumors 
rely heavily on other forms of DNA repair such as base-excision 
repair, resulting in sensitivity to inhibitors of poly-ADP-ribose 
polymerase (PARP1), an enzyme that facilitates repair of single-
stranded breaks (Bryant et al., 2005; Farmer et al., 2005). In nor-
mal cells, the endogenous DNA damage generated by PARP 
inhibition is well-tolerated because of functional compensation 
from homologous recombination-mediated repair. Indeed, mice 
deficient in PARP1 are fertile and do not exhibit increased tumor 
susceptibility (Conde et al., 2001). The addiction of BRCA2 mutant 
cells to PARP1 function is therefore an example of NOA that is 
exploited therapeutically. There are likely to be additional non-
oncogene targets like PARP1 that can be exploited to treat these 
tumors. Likewise, the DNA damage sensitivity of other cancer 
types might also be exploited in this manner, although whether 
generating endogenous damage is superior to adding exogenous 
damage remains to be determined.
Mitotic Stress
As noted above, a variety of tumors display increased rates 
of chromosome mis-segregation, the CIN phenotype, because 
they contain mutations that alter the fidelity of mitosis. Can-cer cells bearing mitotic alterations such as aneuploidy or 
weakened mitotic spindle regulatory machinery are likely to 
exhibit greater reliance on stress support pathways for proper 
chromosome segregation. They are therefore more sensitive 
to catastrophic genomic instability caused by stress overload 
or stress sensitization of the mitotic machinery (Weaver and 
Cleveland, 2005).
The spindle checkpoint can provide stress support in cells 
that have defects in the mitotic machinery, and in such cases 
inhibiting the spindle checkpoint could lead to lethality as a 
result of stress sensitization. Conversely, some tumors with 
the CIN phenotype possess mutations that weaken the spindle 
checkpoint (Cahill et al., 1998) and might be especially sen-
sitive to stress overload caused by the inhibition of proteins 
that carryout mitosis. A notable example of stress overload is 
the microtubule stabilizer taxol, which interferes with proper 
spindle-kinetochore attachment and has shown efficacy 
in the treatment of breast and ovarian cancers (Weaver and 
Cleveland, 2005). Inhibitors of mitotic kinases such as PLK1 
and Aurora-B that also promote stress overload are currently 
undergoing clinical trials (Carpinelli and Moll, 2008; Strebhardt 
and Ullrich, 2006). Aneuploidy itself might be a target of NOA 
as genetic screens in yeast have identified mutations that show 
synthetic lethality with tetraploid verses diploid cells (Storchová 
et al., 2006).
Proteotoxic Stress
Proteotoxic stress is a frequent occurrence in cancer cells 
as a result of the extreme aneuploidy, copy-number varia-
tion, and transcriptional alterations present in tumors. These 
changes alter the dosage balance of protein subunits in dif-
ferent protein complexes and consequently place increased Cell 136, March 6, 2009 ©2009 Elsevier Inc. 829
stress on chaperone pathways to maintain normal homeosta-
sis of the proteome. The heat shock pathway plays a major 
role in promoting protein folding and is activated in many 
tumors (Whitesell and Lindquist, 2005) and is therefore a 
potential NOA target (Figure 2). Studies in yeast have shown 
that an extra copy of a single chromosome is sufficient to 
activate the heat shock response (Torres et al., 2007). Phar-
macological and genetic evidence supports the notion that 
sensitizing tumor cells toward proteotoxic stress can strongly 
suppress tumorigenesis. For example, the chaperone HSP90 
acts to fold newly synthesized proteins and refold mis-folded 
proteins (Whitesell and Lindquist, 2005). The chaperone 
activity of HSP90 requires its ATPase activity, which can be 
inhibited by the anticancer drug geldanamycin. Although the 
antitumor activity of geldanamycin has been attributed to the 
destabilization of key HSP90 client proteins involved in cell 
proliferation such as CDK4 and HER2, it is also possible that 
the sensitization of tumor cells to elevated general proteot-
oxic stress leads to its efficacy.
Additional genetic support for NOA comes from studies of 
HSF1 knockout mice (Dai et al., 2007). HSF1 is the major tran-
scription factor responsible for activating the expression of 
heat shock proteins, including HSP90, in response to excess 
unfolded proteins. Loss of HSF1 markedly reduces tumorigen-
esis driven by either p53 or Ras mutations (Dai et al., 2007). 
Given that neither HSP90 nor HSF1 have been shown to be 
oncogenes, they represent examples of NOA.
Unfolded proteins are generally turned over by the ubiq-
uitin-proteasome pathway. Thus, a second key component of 
the proteotoxic stress response pathway is the proteasome. 
Genetic experiments have shown that the presence of an extra 
chromosome is sufficient to increase the sensitivity of yeast 
cells to proteasome inhibitors (Torres et al., 2007). One prom-
ising new anticancer drug bortezomib (Velcade), which has 
shown efficacy in treating multiple myeloma, acts to inhibit the 
protease function of the proteasome (Richardson et al., 2006). 
As proteasome inhibition is likely to stabilize many different 
proteins, it has been traditionally thought that the stabiliza-
tion of a particular subset of proteins might be responsible for 
the antitumorigenic activity of Velcade. However, it is equally 
likely that its efficacy results from enhanced proteotoxic stress 
leading to stress overload and represents a prime example of 
NOA.
Stress sensitization and stress overload are two sides of 
the same coin. In principle, instead of sensitizing cancer cells 
toward endogenous proteotoxic stress, therapies that enhance 
protein unfolding should overload the stress support network 
in cancer cells, achieving the same result. Normal cells, on the 
other hand, should be less sensitive to such therapies due to 
their low baseline proteotoxic stress. A convenient method of 
inducing protein unfolding is temperature elevation. Indeed, 
hyperthermia is being extensively investigated as a tumor 
treatment for colon, breast, testicular, prostate, and liver can-
cers and has been the subject of ongoing clinical trials, often in 
combination with chemotherapy (Fiorentini and Szasz, 2006). 
The induction of protein unfolding by hyperthermia could pro-
vide a rationale for the efficacy of this approach. Strong sup-
port for this explanation again comes from yeast where it was 830 Cell 136, March 6, 2009 ©2009 Elsevier Inc.shown that the presence of just one extra chromosome results 
in enhanced temperature sensitivity, consistent with a general 
sensitivity to temperature for aneuploid cells (Torres et al., 
2007).
Metabolic Stress
Tumor cells exhibit altered metabolic behavior due to both cell-
intrinsic properties and the tumor microenvironment. As noted 
above, tumor cells have increased glucose uptake and prefer-
entially metabolize glucose through glycolysis even in the pres-
ence of oxygen. Although the reason for the Warburg effect 
is unclear, it has been suggested that such adaptation allows 
the tumor cell to divert resources toward biosynthesis, reduce 
the generation of ROS through mitochondrial oxidative phos-
phorylation, and cope with fluctuating oxygen availability in the 
tumor vicinity (DeBerardinis et al., 2008; Kroemer and Pouys-
segur, 2008). Inhibition of the glycolytic/biosynthetic pathways 
in a tumor cell will lead to stress overload due to incompatibility 
with the persistent proliferative drive from oncogenes (Vander 
Heiden et al., 2001). Indeed, inhibition of ATP citrate lyase 
(which synthesizes acetyl-CoA from citrate), RNAi knockdown 
of lactate dehydrogenase A (the enzyme that converts pyruvate 
to lactate in the last step of glycolysis), and inhibitors against 
acetyl-CoA carboxylase and fatty acid synthase (which control 
the conversion of acetyl-CoA to manonyl-CoA to palmitate) all 
lead to substantial attenuation of tumor cell growth (DeBerar-
dinis et al., 2008; Kroemer and Pouyssegur, 2008). Recently, 
it has been shown that the mere switching of pyruvate kinase 
from one splice variant (M2) commonly expressed in tumor 
cells to another splice variant (M1) can negatively impact the 
tumorigenic state, presumably by shunting pyruvate to the 
TCA cycle (Christofk et al., 2008). Thus targeting key metabolic 
enzymes that constitute NOA could effectively attenuate tumor 
cell proliferation.
Oxidative Stress
Tumor cells often show increased levels of intracellular ROS 
(Szatrowski and Nathan, 1991). Multiple causes contribute to 
ROS generation. Hypoxia-reperfusion in the tumor microenvi-
ronment can lead to ROS production, which in turn can initiate 
a viscous cycle of mitochondrial damage and further ROS gen-
eration (Gogvadze et al., 2008). In addition, oncogenes such 
as Ras can stimulate ROS production, a mechanism that has 
been implicated as an underlying cause of oncogene-induced 
senescence (Lee et al., 1999). ROS cause oxidative damage 
to DNA, proteins, lipids, and other cellular components and 
therefore pose a significant cellular stress (Figure 1). Cancer 
cells partially alleviate this stress by engaging glycolysis and 
downregulating mitochondrial function (Gogvadze et al., 2008). 
Agents that enhance ROS production, therefore, are expected 
to cause stress overload in cancer cells. In support of this 
notion, it has been shown that dichloroacetate, which inhibits 
pyruvate dehydrogenase kinase (PDK) and therefore stimulates 
mitochondrial oxidative phosphorylation and ROS production, 
can selectively elicit apoptosis in cancer cells but not in normal 
cells (Bonnet et al., 2007). Similarly, reducing the cellular ROS 
buffering capacity through the inhibition of glutamate-cysteine 
ligase (a rate-limiting enzyme in cellular glutathione synthe-
sis) can markedly increase the radiosensitivity of cancer cells 
(Diehn et al., 2009).
Hypoxia and Nutrient Stress
Solid tumors, due to poor and abnormal tumor vasculature 
(see below), often suffer from suboptimal oxygen and nutrient 
supplies. This stress underlies the requirement for augmented 
angiogenesis (Figure 1). Consequently many tumors upregulate 
the transcription factor hypoxia-inducible factor HIF-1 (Pouys-
segur et al., 2006). HIF-1 initiates a coordinated transcriptional 
program to both stimulate vessel sprouting (through the induc-
tion of VEGF-A and angiopoietin-2) and promote glycolysis 
(through the induction of glucose transporter 1, hexokinase, 
lactate dehydrogenase, and pyruvate dehydrogenase kinase 
1). Furthermore, HIF-1 protects tumor cells from acidosis and 
promotes the extrusion of lactate by inducing carbonate anhy-
drases, monocarboxylate transporter MCT4, and the Na+/H+ 
exchanger NHE1. Drugs targeting either HIF-1 or its effector 
pathways will therefore sensitize tumor cells toward hypoxic 
stress. Indeed, anti-angiogenic therapies have been effective 
in various clinical settings (see below). Inhibiting the monocar-
boxylate transporter, which would result in intracellular lactate 
accumulation and acidosis, might also be a viable approach 
to selectively kill hypoxic tumor cells addicted to glycolysis 
(Pouyssegur et al., 2006).
As tumor cells grow away from the vasculature system, they 
experience nutrient stress and can resort to autophagy for sur-
vival. Although impaired autophagy could contribute to onco-
genesis by promoting genomic instability and cytokine release 
(Mathew et al., 2007), autophagy is critical for the survival of 
apoptosis-resistant tumor cells during nutrient or growth factor 
restriction. Inhibiting autophagy in such cells would sensitize 
them toward metabolic stress and promote necrotic death. In 
support of this notion, the autophagy inhibitor chloroquine has 
been shown to synergize with DNA damage to induce tumor 
cell death in mice (Jin and White, 2007).
Immune Response Modulation
Most tumors express antigens that could potentially elicit an 
immune response due to the expression of a mutant protein 
that gives rise to a novel epitope. However, in the vast major-
ity of cases tumors are able to prevent rejection by effectively 
suppressing an immune response in the tumor microenviron-
ment (Muller and Scherle, 2006; Zou, 2005). Although not a 
stress phenotype, there are examples of NOA that can be 
used to reverse this hallmark. Several mechanisms protect 
tumor cells from immune surveillance. Tumor cells can down-
regulate the expression of major histocompatibility complex 
(MHC) molecules to reduce antigen presentation (Garrido and 
Algarra, 2001). Tumor cells also synthesize and release a num-
ber of immunomodulatory factors such as chemokines (e.g., 
CCL2), cytokines (e.g., IL6 and IL10), and prostaglandins (e.g., 
PGE2) to suppress the activation of cytotoxic T cells (Sharma 
et al., 2005). Furthermore, the depletion of key metabolites in 
the tumor microenvironment, such as glucose, also inhibits 
cytotoxic T cell expansion (Muller and Scherle, 2006) .
The tumor’s addiction to “immunosuppressive” NOA genes 
could be exploited for therapeutic gains. For example, the 
cycloxygenase-2 (COX2) inhibitor celecoxib, which blocks 
PGE2 synthesis, has been shown to enhance immune response 
to tumors in mice (Stolina et al., 2000). Reactivating MHC gene 
expression in tumor cells that have downregulated MHC, per-haps by inhibiting a histone deacetylase (HDAC) or a transcrip-
tional repressor, is yet another potential means to enhance 
tumor immune surveillance. Active immunization against tumor 
antigens has been shown to be greatly enhanced by interfer-
ing with inhibitory T cells through the use of anti-CTLA-4 anti-
bodies, providing another example of NOA-like therapy (Peggs 
et al., 2008). A major attraction of re-establishing the antitu-
mor immune response is that one could potentially apply it in 
a systematic manner toward many tumor types and allow the 
immune system to detect and eradicate tumors at a relatively 
early stage.
Extrinsic Non-oncogene Addiction
Angiogenesis
One of the best examples of extrinsic NOA is the ability of solid 
tumors to recruit new blood vessels through the secretion of 
angiogenic factors. Tumor angiogenesis ensures that cells in 
the interior of the tumor receive sufficient nutrients and oxy-
gen to survive. Blocking tumor angiogenesis would therefore 
severely restrict tumor growth (Folkman, 2007). Early experi-
ments using mouse xenografts indicated that antibody-medi-
ated inhibition of vascular endothelial growth factor (VEGF), 
which promotes the proliferation and migration of vascular 
endothelial cells and vessel sprouting, could severely constrain 
angiogenesis and tumor growth (Kim et al., 1993). These and 
other studies led to the development of the anti-VEGF antibody 
bevacizumab for therapeutic use (Ferrara et al., 2004). Addi-
tionally, the small-molecule inhibitors sorafenib and sunitinib, 
which target multiple receptor tyrosine kinases including VEGF 
receptors, have shown efficacy in treating metastatic renal cell 
carcinoma (Escudier et al., 2007; Motzer et al., 2006). In prin-
ciple, any protein required for angiogenesis in endothelial cells 
is a candidate for extrinsic NOA.
Stromal Support
The tumor stroma plays a key role in supporting tumor growth 
(Hu and Polyak, 2008). It is increasingly clear that heterotypic 
interactions between the tumor and its surrounding stromal 
cells lead to phenotypic changes in the stroma that better sup-
port tumor growth. For example, the myofibroblasts surround-
ing breast tumors are distinct from normal mammary stromal 
fibroblasts in their ability to secrete stromal-derived factor 1 to 
both stimulate tumor growth and recruit endothelial progeni-
tor cells for angiogenesis (Orimo et al., 2005). This phenotypic 
distinction is further supported by substantial gene expression 
and epigenetic changes observed in these cancer-associated 
stromal cells (Allinen et al., 2004). In addition, bone marrow-
derived mesenchymal stem cells and hematopoietic progeni-
tors have been found to play important roles in tumor metas-
tasis either through cytokine-mediated paracrine signaling or 
through their mobilization to distal sites to help establish the 
metastatic niche, respectively (Kaplan et al., 2005; Karnoub et 
al., 2007). Although somatic mutations in tumor stromal cells 
are rare (Allinen et al., 2004; Qiu et al., 2008), in the case of 
familial neurofibromatosis 1 caused by mutations in the NF1 
gene, careful modeling of the disease in mice has revealed a 
striking contribution of mast cells to tumor development. The 
contribution of NF1 heterozygous mast cells and bone mar-
row cells to the disease phenotype is dependent on signaling Cell 136, March 6, 2009 ©2009 Elsevier Inc. 831
by c-kit in these cells, a receptor readily inhibited by imatinib. 
Indeed, imatinib was successfully applied to reduce the tumor 
burden of an NF1 patient (Yang et al., 2008), thus demonstrating 
the utility of targeting tumor-extrinsic NOA pathways for cancer 
therapy. We have used the stress phenotypes to illustrate NOA; 
however, it is important to realize that other examples of NOA 
pathways exist unrelated to stress that when inhibited will also 
be incompatible with the oncogenic state.
The Path Ahead to New Cancer Therapeutics
We are approaching a new era in cancer research as we now 
have the tools to mount a systematic assault on the problem of 
tumorigenesis in terms of both understanding the underlying 
pathogenic process and devising new therapies to treat can-
cer. Below we explore new approaches for identifying cancer 
drug targets and provide theoretical considerations of how 
therapies attacking cancer might be optimally applied.
Approaches to Target Identification
Having outlined the different classes of potential cancer targets 
based on their underlying cellular functions, what is the best 
approach that we as cancer researchers can take to quickly 
generate therapies that are so desperately needed? Clearly 
target identification and patient stratification, that is, the ability 
to group patients with common biomarkers to link them to the 
appropriate therapy, will play a major part in the evolution of new 
therapies. Thus, new biomarkers and means to identify thera-
peutic targets are needed. In a general sense, the approaches 
that served us so well in the first era of cancer research—the 
painstaking identification of individual genes and attempts to 
exploit them to cure cancer—will likely not suffice for the next 
era of cancer research. Systems-level approaches are needed 
to identify the vulnerabilities of cancer cells in a genome-wide 
and unbiased manner. Two such complementary and mutu-
ally reinforcing efforts are underway and should systematically 
identify candidate drug targets, providing a blueprint for can-
cer drug target discovery.
The first is the traditional approach to identify genetic lesions in 
cancer cells and exploit this knowledge for therapeutics, a tried 
and true method that has led to the identification of several drug 
targets. Such an approach is currently employed by The Cancer 
Genome Atlas and other similar efforts that aim to characterize, 
in a large number of cancer types, genomic alterations includ-
ing copy-number variation, transcriptional profiles, epigenetic 
modifications, and DNA sequence alterations. While expensive, 
this approach has the potential to identify common alterations in 
oncogenes and tumor suppressors for further functional analy-
sis and uncover oncogene addiction pathways that can be tar-
geted (Cancer Genome Atlas Research Network, 2008; Jones 
et al., 2008; Parsons et al., 2008). It is clear that these efforts 
will yield important new information on human cancer and aid 
biomarker discovery and patient stratification. However, this 
approach has two limitations with respect to target discovery. 
First, current sequencing capacity is primarily limited to coding 
regions, though whole-genome sequencing will become feasi-
ble with cheaper and more highly parallel sequencing methods. 
The second limitation is that this approach will not discover NOA 
pathways that support tumorigenesis, such as those discussed 
above, because they are not mutated in cancers.832 Cell 136, March 6, 2009 ©2009 Elsevier Inc.The second approach takes a more functional, systems-
biology approach to identify cancer cell vulnerabilities (Ngo et 
al., 2006; Schlabach et al., 2008; Silva et al., 2008). This has 
been made possible by the RNA interference (RNAi) revolution. 
Advances in RNAi technology in mammalian cells have made 
it possible, for the first time, to systematically interrogate every 
cellular protein for potential addiction by cancer cells. A func-
tional approach using RNAi offers several advantages in target 
discovery. First, RNAi-mediated protein knockdown results in 
either partial or complete loss of function, which in many cases 
closely mimics the effect of an inhibitor. Second, RNAi can be 
applied to any annotated gene in the human genome based 
on sequence information alone without the a priori knowledge 
of the gene’s cellular function or mutational status in cancer. 
Therefore, this approach will uncover both known and new 
genes that were not previously implicated in cancer. Third, RNAi 
can be readily applied to animal models (Dickins et al., 2007). 
This provides rapid, in vivo target validation that takes advan-
tage of the many mouse models of cancer, without the need 
to first develop an inhibitor. Lastly and importantly, genome-
wide RNAi screening will identify genes that are not mutated in 
cancers and exhibit features of NOA. Systematic RNAi screens 
aimed to generate either “synthetic lethal signatures” against 
specific oncogenes or tumor suppressors or “cancer lethal sig-
natures” using a large panel of cancer and normal cells should 
reveal a genetic landscape of cancer vulnerabilities that guide 
the rational design of therapeutic approaches.
A current limitation of the RNAi approach is the fact that 
many screens are being performed in cell lines in vitro and are 
limited to analysis of genes important for proliferation and sur-
vival. Thus, these screens will miss certain classes of genes 
that might function only in the proper in vivo tumor environ-
ment. This limitation can be overcome, however, if large-scale 
genetic screens can be approached systematically in mice with 
defined cancer models. Continuous RNAi library development 
that aims to improve gene knockdown efficiency and incorpo-
rate features (such as barcodes) that enable very high through-
put screening will further enhance the power of this approach. 
These efforts would require a sustained commitment of 
resources, such as an organized consortium effort, but would 
result in the identification and validation of critical cancer drug 
targets in a relatively unbiased, comprehensive fashion. Given 
the long-standing success of genetics in providing unbiased 
insights into biology and disease mechanisms, our goal should 
be nothing less than identifying all the pathways upon which 
cancer cells depend to maintain the oncogenic state.
The identification of drug targets is only the first step in the 
process to develop new cancer therapeutics. The ability to 
identify or design small-molecule inhibitors with the appro-
priate pharmacological properties against any given target is 
the next challenge. Currently, many efforts focus only on the 
so-called “druggable genome,” which represents proteins with 
enzymatic functions that can be easily assayed or targeted. 
However, recent studies have shown that many proteins previ-
ously thought to be difficult to target can, in fact, be inhibited 
by small molecules (Wells and McClendon, 2007). New meth-
ods of identifying small molecules based on their ability to bind 
specific proteins and disrupt protein-protein interaction should 
widen the playing field and allow more validated targets that 
emerge from physical mapping and genetic screens to enter 
the drug development pipeline. Of course, it is widely hoped 
that RNAi itself will become a cancer therapy in the near future 
once a solution to its effective delivery to tumors is found. If so, 
this will circumvent many limitations inherent to small-molecule 
inhibitors and revolutionize drug development.
Mathematical Elimination of Cancer using Orthogonal 
Therapies
It is very likely that the oncogenes and non-oncogenes to 
which tumors are addicted will serve as the targets of success-
ful cancer therapies in the future. However, it is already clear 
that each of even the best therapies applied alone eventually 
fail in the majority of cases. Each therapy can be considered to 
be a filter that removes a set of cancer cells with certain prop-
erties (Figure 3). However, a subset of tumor cells slip through 
the filter to eventually establish clones, rendering the therapy 
ineffective. These rare, pre-existing mutant cells contain sup-
pressor mutations that circumvent the therapy. Examples of 
suppressor mutations might include an altered drug-binding 
site on the intended target, amplification of the drug target, 
activation of drug efflux pumps, or activation of an alternative 
pathway, such as a growth factor signaling pathway, that per-
forms the same function as the inhibited pathway. The rate of 
appearance of suppressor mutations is an important parameter 
in cancer therapies. Unfortunately, one of the inherent proper-
ties of cancer cells is their enhanced genomic instability, which 
accelerates the appearance of suppressor mutations.
From a theoretical perspective, in order to overcome this 
problem, a combinatorial series of filters applied concurrently 
is needed to eliminate all of the cancer cells in a patient. How 
this will be accomplished remains to be determined, but we 
envision it to be the simultaneous application of orthogonal 
cancer therapies. Two therapies are considered orthogonal, 
and therefore act synergistically, when they attack a cancer 
in two different ways such that a suppressor mutation for the 
first therapy cannot suppress the second therapy and vice 
versa. It should be noted that some non-orthogonal therapies 
might also have efficacy in combination if only a portion of the 
suppressors can overcome both therapies. This leads to the 
simple mathematical proposition that the probability of can-
cer escaping the therapies, the recurrence index, RI, will be 
proportional to the number of cancer-initiating cells, N, times 
the frequency of suppressor mutations for therapy 1, v1, times 
the frequency of suppressor mutations for therapy 2, v2, and 
so on to produce RI = Nv1v2…vi. Once RI becomes much less 
than 1, the probability of surviving the cancer is high. Impor-
tantly, this general treatment takes full consideration of tumor 
cell heterogeneity such as the existence of “cancer stem cells” 
that might have a different property than the bulk of the tumor. 
Although the values of the parameters in this equation are not 
currently known and are likely to vary based on tumor type, it is 
clear that such an approach can work as it is analogous to the 
treatment of HIV. For HIV, which resembles tumors in that it is 
highly mutable, a triple cocktail of inhibitors of HIV replication 
can control the progression of the disease. We envision that 
cancer therapies will adopt this calculus and convert cancer, 
like AIDS, from a terminal illness to a chronic disease or even provide a cure. Given that cancer is actually a collection of dis-
tinct diseases, the orthogonal combinations will vary depend-
ing upon the tumor genotype and possibly the genotype of the 
patient. It is likely that the treatment regimen employed will be 
determined by the analysis of a series of biomarkers in each 
tumor that have been previously shown to predict efficacy of a 
particular therapy. Combinatorial therapies are currently being 
considered for a number of cancers. However, it will be impor-
tant to understand the nature and frequency of suppressors 
that allow escape from each therapy when designing combina-
tions in order to maximize the orthogonality of the combinato-
rial therapies. In addition, it is critical that such therapies, when 
tolerated by patients, be applied concurrently, not sequen-
tially, because the latter will allow the number of cancer-ini-
tiating cells, N, to expand prior to the subsequent treatment, 
thereby increasing the RI. Finally, it should be noted that if one 
of the therapies employed is a DNA-damaging agent, it might 
increase the frequency of suppressor mutations for the other 
therapies with which it is combined.
In summary, there are many avenues through which to 
approach future cancer therapies. We hope these additional 
hallmarks depicting the stress phenotypes of cancer cells will 
both improve our understanding of the efficacy of existing 
therapies and provide rationales for new therapeutics. Cancer 
Figure 3. The Combinatorial Filter of Orthogonal Cancer Therapies
A tumor consists of genetically distinct subpopulations of cancer cells (repre-
sented by the different cell shapes), each with its own characteristic sensitiv-
ity profile to a given therapeutic agent. Each cancer therapy can be viewed 
as a filter that removes a subpopulation of cancer cells that are sensitive to 
this treatment while allowing other insensitive subpopulations to escape. This 
escape occurs as a result of suppressor mutations that occur at a given fre-
quency (v) unique to each therapy and tumor type. By combining therapies 
with orthogonal modes of action, a combinatorial filter can be set up to mini-
mize the recurrence index (RI) of the cancer. N represents the total number of 
cancer cells in the tumor. A combination of orthogonal therapies that result in 
RI < 1 would greatly enhance the likelihood of preventing tumor recurrence.Cell 136, March 6, 2009 ©2009 Elsevier Inc. 833
therapeutic targets can emerge through both the analysis of 
classical oncogenes and the analysis of a new class of genes 
that constitute NOA. New genome-wide efforts to approach 
cancer from a systems-biology perspective hold great prom-
ise for identifying new targets for anticancer therapies. Finally, 
we propose that through the proper combination of orthogonal 
cancer therapies, it is possible to convert cancer from a death 
sentence into a manageable or even curable disease.
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